Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Head and Neck Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides valuable insights, covering statistics on market size, regional shares, competitors, market trends, and opportunities.
The head and neck squamous cell carcinoma market is experiencing significant growth, with its size projected to expand from $1.97 billion in 2025 to $2.15 billion in 2026 at a CAGR of 9%. This growth is attributed to the increasing prevalence of tobacco and alcohol consumption, rising diagnosis rates, and advancements in oncology drug pipelines. Improved diagnostic accuracy and the availability of hospital-based cancer treatments are also fueling the market.
Looking towards the future, the market is expected to grow further to $3.02 billion by 2030, maintaining a robust CAGR of 8.8%. Anticipated growth drivers include increasing investments in immuno-oncology research, a growing demand for personalized cancer therapies, and the expansion of molecular diagnostics. Emerging trends such as the adoption of immune checkpoint inhibitors, biomarker-based treatment selections, and combination therapy regimens are poised to shape the market landscape.
The rise in tobacco and alcohol consumption continues to be a significant factor affecting market growth. These substances contribute to carcinogenesis in the head and neck region by damaging the mucosal lining and promoting genetic mutations. For instance, a 2023 report by Action on Smoking and Health revealed that 11.9% of UK adults were smokers, equating to about 6 million cigarette users nationally.
Strategic partnerships are on the rise among companies in this market, aimed at developing innovative combination therapies. These collaborations facilitate resource pooling, accelerate research and development, and expand market access. A notable example is the partnership between Exelixis Inc. and Merck & Co. Inc. in October 2024, focused on evaluating the combination of zanzalintinib with KEYTRUDA and WELIREG for better treatment outcomes.
In a strategic merger, Flamingo Therapeutics NV and Dynacure SAS joined forces in March 2023. This merger combines expertise in RNA-targeting and clinical drug development, forming a leading oncology company focused on innovative therapies, including Flamingo's danvatirsen program currently in Phase II trials.
Leading companies in this field include Pfizer Inc., Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, and several others. North America remains the largest region in this market, while Asia-Pacific is projected to be the fastest growing during the forecast period.
Reasons to Purchase:
- Achieve a global perspective with coverage across 16 geographies.
- Evaluate macro factors like geopolitical influences, trade policies, inflation, and regulatory changes.
- Formulate regional and country-level strategies based on localized data and insights.
- Identify lucrative growth segments for investment opportunities.
- Leverage forecast data, market trends, and drivers to gain a competitive edge.
- Enhance customer understanding through end-user analysis.
- Benchmark against competitors on metrics like market share and innovation.
- Gauge market potential using Total Addressable Market (TAM) and Market Attractiveness Scoring (MAS).
- Utilize reliable data for both internal and external presentations.
- Receive the latest data updates along with an Excel data sheet for streamlined analysis.
Markets Covered:
- By Type: Oral and Oropharyngeal, Nasal Cavity and Paranasal Sinuses, Laryngeal, Hypopharyngeal
- By Drug Class: EGFR Inhibitors, Immune Checkpoint Inhibitors
- By Route of Administration: Intravenous, Oral
- By Treatment: Radiation Therapy, Chemotherapy, Immunotherapy
- By End-user: Hospitals, Specialty Clinics
Regions and Companies: Examination covers countries including Australia, Brazil, China, and more, alongside analysis of companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, and Merck & Co. Inc.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.15 Billion |
| Forecasted Market Value (USD) by 2030 | $3.02 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
The companies featured in this Head and Neck Squamous Cell Carcinoma market report include:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- GSK plc
- Eli Lilly and Company
- Bayer AG
- Sanofi SA
- Boehringer Ingelheim International GmbH
- Rakuten Medical Inc.
- Exelixis Inc.
- Akeso Inc.
- MacroGenics Inc.
- Immutep Limited
- Nykode Therapeutics AS
- Checkpoint Therapeutics Inc.
- Hookipa Pharma Inc.
- Turnstone Biologics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/nalsfs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
